In the wake of increased interest in the GLP-1 mimetics for weight loss, we have reviewed this drug class. On re-examination of the evidence, we believe that delayed gastric emptying is unlikely to cause a clinically significant interaction with our primary drugs. Certain DAAs, however, (ledipasvir, ravidasvir, velpatasvir) are sensitive to increased gastric pH, which may occur with the decreased gastric secretions associated with GLP-1 mimetics, and these interactions are coded yellow. Finally, all interactions with sorafenib are yellow due to a class effect.
We have added the following GLP-1 mimetics to the interaction checker:
- Semaglutide (Ozempic, Wegovy)
- Tirzepatde (Mounjaro)
